期刊
PATHOGENS
卷 12, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/pathogens12020194
关键词
zika virus; live-attenuated vaccine; vaccine platform
类别
ZIKV is a re-emerging mosquito-borne flavivirus that has caused outbreaks worldwide, and it poses a major threat to global public health. The development of a safe and effective vaccine is a global health priority. Multiple platforms have been used to develop candidate ZIKV vaccines, some of which have shown promising results in animal models and progressed to clinical trials. Live-attenuated vaccines are considered one of the most important strategies for controlling flavivirus diseases.
Zika virus (ZIKV), a re-emerging mosquito-borne flavivirus, has caused outbreaks in Africa, Asia, the Pacific, and, more recently, in the Americas. ZIKV has been associated with the neurological autoimmune disorder Guillain-Barre syndrome in adults and congenital Zika syndrome in fetuses and infants, including microcephaly, spontaneous abortion, and intrauterine growth restriction. It is considered to be a major threat to global public health due to its unprecedented clinical impact on humans. Currently, there are no specific prophylactics or therapeutics available to prevent or treat ZIKV infection. The development of a safe and efficacious ZIKV vaccine remains a global health priority. Since the recent outbreak, multiple platforms have been used in the development of candidate ZIKV vaccines. The candidate vaccines have been shown to elicit strong T cell and neutralization antibody responses and protect against ZIKV infection in animal models. Some candidates have progressed successfully to clinical trials. Live-attenuated vaccines, which induce rapid and durable protective immunity, are one of the most important strategies for controlling flavivirus diseases. In this review, we discuss recent progress in the development of candidate live-attenuated ZIKV vaccines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据